NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides Physician Tablet, Patient Data Management System, and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Neuropace Inc.

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on NeuroPace, with a price target of $20.00. Takkinen covers th...

Lake Street Keeps Their Buy Rating on NeuroPace (NPCE)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on NeuroPace today and set a price target of $16.00. Biegelsen covers the Healthcare se...

Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE)

In a report released today, Priya Sachdeva from UBS reiterated a Buy rating on NeuroPace, with a price target of $18.00. According to TipRanks, Sac...

UBS Keeps Their Buy Rating on NeuroPace (NPCE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NeuroPace (NPCE – Research Report) and Evaxion Biote...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NPCE	$16.19	-0.98%	58.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NPCE	$16.19	-1.0%	58.77K
3
4
5
6

NPCE

NPCE

Get Neuropace Inc. Data in Excel

Get Neuropace Inc. Data in Excel